Treatment of acute myeloid leukemia with 20-30% bone marrow blasts.

about

Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients.Successful re-treatment with azacitidine in a patient with low blast count AML transformed from MDS after suspension of this agent.

P2860

Q38161965-CBF89DFA-3D89-4A4E-A177-E94594A8CCC2 Q41582427-CD9B8BE9-5C48-495B-9691-EA11EC99DBF1

P2860

Treatment of acute myeloid leukemia with 20-30% bone marrow blasts.

Item

http://www.wikidata.org/entity/Q36934199

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Treatment of acute myeloid leukemia with 20-30% bone marrow blasts.

@en

type

Item

label

Treatment of acute myeloid leukemia with 20-30% bone marrow blasts.

@en

prefLabel

Treatment of acute myeloid leukemia with 20-30% bone marrow blasts.

@en

P1476

Treatment of acute myeloid leukemia with 20-30% bone marrow blasts.

@en

P2093

Adriano Venditti

http://www.w3.org/2001/XMLSchema#string

Chiara Sarlo

http://www.w3.org/2001/XMLSchema#string

Concetta Ditto

http://www.w3.org/2001/XMLSchema#string

Daniela Nasso

http://www.w3.org/2001/XMLSchema#string

Eleonora Ceresoli

http://www.w3.org/2001/XMLSchema#string

Federica Giannotti

http://www.w3.org/2001/XMLSchema#string

Francesco Buccisano

http://www.w3.org/2001/XMLSchema#string

Luca Maurillo

http://www.w3.org/2001/XMLSchema#string

Luigi Di Caprio

http://www.w3.org/2001/XMLSchema#string

Marco Refrigeri

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

The World Health Organization (WHO) classification of the myeloid neoplasms

Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the Germa

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

Proposals for the classification of the myelodysplastic syndromes

Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients

International scoring system for evaluating prognosis in myelodysplastic syndromes

Cancer epigenetics comes of age

Prediction of survival for advanced cancer patients by recursive partitioning analysis: role of Karnofsky performance status, quality of life, and symptom distress.

Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.

P304

e2013032

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4084/MJHID.2013.032

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23795270

http://www.w3.org/2001/XMLSchema#string

P932

3684350

http://www.w3.org/2001/XMLSchema#string

Treatment of acute myeloid leukemia with 20-30% bone marrow blasts.

about

P2860

P2860

Treatment of acute myeloid leukemia with 20-30% bone marrow blasts.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932